The mTOR Inhibitor RAD 001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p 21 Translation
暂无分享,去创建一个
H. Lane | F. Natt | Jonathan Hall | T. O'reilly | S. Ruetz | I. Beuvink | G. Thomas | S. Fumagalli | A. Boulay | Frédéric Zilbermann | Iwan Beuvink
[1] N. Sonenberg,et al. Upstream and downstream of mTOR. , 2004, Genes & development.
[2] T. Golub,et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways , 2004, Nature Medicine.
[3] Stefano Fumagalli,et al. S6K1−/−/S6K2−/− Mice Exhibit Perinatal Lethality and Rapamycin-Sensitive 5′-Terminal Oligopyrimidine mRNA Translation and Reveal a Mitogen-Activated Protein Kinase-Dependent S6 Kinase Pathway , 2004, Molecular and Cellular Biology.
[4] Frank McCormick,et al. Cancer: Survival pathways meet their end , 2004, Nature.
[5] S. Lowe,et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy , 2004, Nature.
[6] J. Dutcher,et al. Mammalian target of rapamycin (mTOR) inhibitors , 2004, Current oncology reports.
[7] W. Leung,et al. Upregulation of heme oxygenase-1 and p21 confers resistance to apoptosis in human gastric cancer cells , 2004, Oncogene.
[8] J. Mester,et al. Rapamycin inhibits cdk4 activation, p 21WAF1/CIP1 expression and G1‐phase progression in transformed mouse fibroblasts , 2004, International journal of cancer.
[9] H. Lane,et al. Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear Cells , 2004, Cancer Research.
[10] A. Jaeschke,et al. mTOR: a mediator of intracellular homeostasis. , 2004, Current topics in microbiology and immunology.
[11] C. Proud,et al. Role of mTOR signalling in the control of translation initiation and elongation by nutrients. , 2004, Current topics in microbiology and immunology.
[12] John L Cleveland,et al. Myc pathways provoking cell suicide and cancer , 2003, Oncogene.
[13] Z. Siddik,et al. Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.
[14] M. Pagano,et al. Proteasome-Mediated Degradation of p21 via N-Terminal Ubiquitinylation , 2003, Cell.
[15] N. Socci,et al. Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. , 2003, Molecular cell.
[16] G. Prendergast. Signal transduction: putting translation before transcription. , 2003, Cancer cell.
[17] Shile Huang,et al. Targeting mTOR signaling for cancer therapy. , 2003, Current opinion in pharmacology.
[18] Shile Huang,et al. Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). , 2003, Molecular cell.
[19] E. Hafen,et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. , 2003, Molecular cell.
[20] M. Kralj,et al. Endogenous p21WAF1/CIP1 status predicts the response of human tumor cells to wild-type p53 and p21WAF1/CIP1 overexpression , 2003, Cancer Gene Therapy.
[21] B. Edgar,et al. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins , 2003, Nature Cell Biology.
[22] Shile Huang,et al. Rapamycins: Mechanisms of Action and Cellular Resistance , 2003, Cancer biology & therapy.
[23] M. Eilers,et al. Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter , 2003, Oncogene.
[24] R. Weiss,et al. Suppression of breast cancer growth and angiogenesis by an antisense oligodeoxynucleotide to p21(Waf1/Cip1). , 2003, Cancer letters.
[25] T. Decker,et al. reduced expression of cyclin D3, cyclin E, cyclin A and survivin Rapamycin induced G1 arrest in cycling B-CLL cells is associated with , 2013 .
[26] Steven J. Marygold,et al. Growth Signaling: TSC Takes Its Place , 2002, Current Biology.
[27] K. Vousden. Switching from life to death: the Miz-ing link between Myc and p53. , 2002, Cancer cell.
[28] A. Hodges,et al. Tuberous sclerosis complex tumor suppressor–mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent , 2002, The Journal of cell biology.
[29] Xin Lu,et al. Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.
[30] A. Gartel,et al. The Role of the Cyclin-dependent Kinase Inhibitor p 21 in Apoptosis 1 , 2002 .
[31] F. Luan,et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy1 , 2002, Transplantation.
[32] T. Honjo,et al. DNA Double-Strand Breaks , 2002, The Journal of experimental medicine.
[33] A. Jaeschke,et al. Mammalian TOR: A Homeostatic ATP Sensor , 2001, Science.
[34] T. Owa,et al. Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. , 2001, Current medicinal chemistry.
[35] Shile Huang,et al. p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin. , 2001, Cancer research.
[36] D. Woods,et al. Regulation of p53 function. , 2001, Experimental cell research.
[37] K. Khanna,et al. DNA double-strand breaks: signaling, repair and the cancer connection , 2001, Nature Genetics.
[38] J. Bartek,et al. Pathways governing G1/S transition and their response to DNA damage , 2001, FEBS letters.
[39] P. Houghton,et al. Arrest and Determine the Cellular Response to Rapamycin 1 Cooperate in Enforcing Rapamycin-induced G CIP 1 p 53 / p 21 Updated , 2001 .
[40] T. Jorgensen,et al. p21WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis. , 2000, Cancer research.
[41] G. Thomas,et al. 23 S6 Phosphorylation and Signal Transduction , 2000 .
[42] James M. Roberts,et al. The p21Cip1 and p27Kip1 CDK ‘inhibitors’ are essential activators of cyclin D‐dependent kinases in murine fibroblasts , 1999, The EMBO journal.
[43] T. Tsuruo,et al. Caspase-mediated cleavage of p21Waf1/Cip1 converts cancer cells from growth arrest to undergoing apoptosis , 1999, Oncogene.
[44] W. El-Deiry. The Role of p53 in Chemosensitivity , 1999 .
[45] M. Miura,et al. Resistance to Fas-mediated apoptosis: activation of Caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP , 1998, Oncogene.
[46] Prem Seth,et al. Cleavage of CDK Inhibitor p21Cip1/Waf1 by Caspases Is an Early Event during DNA Damage-induced Apoptosis* , 1998, The Journal of Biological Chemistry.
[47] E. Ségal-Bendirdjian,et al. Alteration in p53 pathway and defect in apoptosis contribute independently to cisplatin-resistance , 1998, Cell Death and Differentiation.
[48] P. O'Connor,et al. Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard , 1997, Oncogene.
[49] J. LaBaer,et al. New functional activities for the p21 family of CDK inhibitors. , 1997, Genes & development.
[50] S. Schreiber,et al. PIK-Related Kinases: DNA Repair, Recombination, and Cell Cycle Checkpoints , 1995, Science.
[51] G. Mills,et al. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. , 1995, Cancer research.
[52] James M. Roberts,et al. lnterleukin-2-mediated elimination of the p27Kipl cyclin-dependent kinase inhibitor prevented by rapamycin , 1994, Nature.
[53] K. Kohn,et al. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. , 1994, Cancer research.